Back to test list

Glioma FISH panel

Also known as: t(1;19) FISH, EGFR FISH, Oligodendroglioma FISH, 1p/19q co-deletion, glioma FISH

Test category:

Oncology - Brain cancer

Use of test

Purpose:

Deletions of 1p and 19q are associated with tumours with oligodendroglial components and is pathognomonic for a distinct glioma entity under the WHO classification system. The co-deletion is due to an unbalanced translocation - t(1;19)(q10;p10). The panel also includes testing for EGFR amplication.

Utility:

Demonstration of co-deletion of 1p and 19q in oligodendroglioma has been shown to be associated with a favourable response to therapy, in addition to being required for accurate diagnosis. EGFR amplification may be associated with poorer prognosis.

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Methodology:

Fluorescent in situ hybridisation (FISH) analysis, using probes to enumerate the 1p and 19q deletion status.

Requesting the test

Ordering:

This test is usually requested by an oncologist. EGFR amplification is usually requested concurrently.

Request form:

Download the solid tumour somatic mutation request form.

Sample required:

Formalin-fixed, paraffin embedded tissue (FFPE) - 15 sections of 4 uM thickness, dried overnight at 37°C onto charged/coated slides.

Special instructions:

Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-15). The request should be accompanied by the somatic mutation request form (above) and a copy of the original histopathology report.

Turnaround time:

5 business days (after receipt of sample by the laboratory).

Price:

$410.

Rebate:

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Click here for our billing policy.